证券代码：002317 公告编号：2025-046 专利权期限：自申请日起二十年 本专利是公司 RAY1225 项目的化合物专利，属于该项目的核心专利。 RAY1225 注射液是一款具有 GLP-1 受体和 GIP 受体双重激动活性的多肽药物， 得益于优异的药代动力学特性，具备每两周注射一次的长效药物潜力。目前 RAY1225 注射液处于 III 期临床试验阶段，后续公司将按计划有序推进项目研发 工作。 截止目前，RAY1225 项目的化合物专利已获得中国、中国台湾、澳大利亚、 俄罗斯、日本的专利授权，此次本项目核心专利的获得有利于公司进一步完善知 识产权保护体系，发挥自主知识产权优势。 广东众生药业股份有限公司 关于控股子公司获得日本专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，广东众生药业股份有限公司（以下简称"公司"）控股子公司广东众 生睿创生物科技有限公司（以下简称"众生睿创"）收到日本特许厅（Japan Patent Office）颁发的专利证书。具体情况如下： 发明名称：ポリペプチドの調製およびその使用（多肽的制备及其应用） ...

众生药业（002317）公告，控股子公司众生睿创收到日本特许厅颁发的专利证书，专利名称为"ポリペ プチドの調製およびその使用"，专利号为7672503，专利申请日为2022年05月30日，专利权人为众生睿 创，专利权期限为自申请日起二十年。该专利为RAY1225项目的化合物专利，属于该项目的核心专 利。RAY1225注射液是一款具有GLP-1受体和GIP受体双重激动活性的多肽药物，目前处于III期临床试 验阶段。此次专利授权有利于公司进一步完善知识产权保护体系，发挥自主知识产权优势，但不会对公 司短期的财务状况、经营业绩构成重大影响。 ...

Group 1: Company Performance - Wens Foodstuff's April chicken sales revenue was 2.543 billion yuan, a year-on-year decrease of 5.01% [1] - Wens Foodstuff sold 10.381 million chickens in April, a year-on-year increase of 10.87% [1] - Wens Foodstuff's average chicken selling price was 11.24 yuan/kg, a year-on-year decrease of 14.91% [1] - Zhongtong Bus's April vehicle sales volume was 1,046 units, a year-on-year decrease of 4.04% [1][2] - Kemin Food's April pig sales revenue reached 70.9048 million yuan, a year-on-year increase of 16.04% [3] - Muyuan Foods sold 6.573 million pigs in April, a year-on-year increase of 51.80% [5] - Muyuan Foods' pig sales revenue was 12.595 billion yuan in April, a year-on-year increase of 53.42% [5] - Xiamen Airport's April passenger throughput was 2.3881 million, a year-on-year increase of 7.73% [24] - Daqin Railway's April cargo transport volume was 30.62 million tons, a year-on-year increase of 0.99% [26] - Shaanxi Coal's April coal production was 14.24 million tons, a year-on-year decrease of 1.78% [28] Group 2: Industry Overview - Wens Foodstuff operates in the agriculture, forestry, animal husbandry, and fishery industry, specifically in pig farming [1] - Zhongtong Bus operates in the automotive industry, focusing on commercial vehicles [2] - Kemin Food operates in the food and beverage industry, specifically in food processing [3] - Muyuan Foods is also in the agriculture, forestry, animal husbandry, and fishery industry, focusing on pig farming [5] - Xiamen Airport is part of the transportation industry, specifically in airport operations [24] - Daqin Railway operates in the coal industry, focusing on coal mining and transportation [26] - Shaanxi Coal is also in the coal industry, focusing on coal mining and related services [28]

Summary of the Conference Call on ZHONGSHENG PHARMACEUTICAL's GLP-1/GIP Dual-target Drug RAY1225 Industry and Company Overview - The conference call focuses on ZHONGSHENG PHARMACEUTICAL, specifically its subsidiary's GLP-1/GIP dual-target drug RAY1225, which is aimed at treating obesity and Type 2 Diabetes (T2D) [1]. Core Insights and Arguments - The Phase 2 clinical trial data for RAY1225 was presented, highlighting the results from two studies: REBUILDING-1 and SHINING-1, with a dosing schedule of once every two weeks for 24 weeks [1]. - Weight loss results for the 3mg, 6mg, and 9mg groups were reported as follows: - 3mg group: -10.05% - 6mg group: -12.98% - 9mg group: -15.05% - Placebo group: -3.55% [1]. - HbA1c reduction for the same groups was noted: - 3mg group: -1.68% - 6mg group: -2.06% - 9mg group: -2.16% - Placebo group: -0.33% [1]. - Comparative data from a similar drug, Tirzepatide, was also discussed: - In the Tirzepatide Phase 3 data, the 15mg group showed a weight loss of approximately -12% (after adjusting for placebo) [1]. - In the Tirzepatide Phase 2 data, HbA1c reductions for the 1mg, 5mg, 10mg, and 15mg groups were reported as: - 1mg: -1.06% - 5mg: -1.73% - 10mg: -1.89% - 15mg: -1.94% - Placebo group: -0.06% [1]. Other Important but Potentially Overlooked Content - The data indicates that RAY1225 shows promising efficacy in weight loss and glycemic control compared to the placebo, suggesting a competitive position in the obesity and T2D treatment market [1]. - The results from both RAY1225 and Tirzepatide highlight the potential for dual-target therapies in managing obesity and T2D, which may attract investor interest in the pharmaceutical sector [1].

证券代码：002317 公告编号：2025-045 广东众生药业股份有限公司 关于控股子公司一类创新药 RAY1225 注射液 II 期临床试验获得顶线分析数据结果的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）控股子公司广东众生睿创 生物科技有限公司（以下简称"众生睿创"）自主研发的一类创新多肽药物 RAY1225 注射液，于近日获得减重和降糖两项 II 期临床试验剂量扩展组的顶线 分析数据。初步结果表明，RAY1225 注射液 3~9 mg 在中国成人肥胖/超重参与 者和 2 型糖尿病参与者中表现出积极的疗效和良好的安全性，试验结果理想，达 到预期目的。具体情况如下： 一、RAY1225 注射液两项 II 期临床试验情况 RAY1225 注射液是众生睿创研发的、具有全球自主知识产权的创新结构多 肽药物，具有 GLP-1 受体和 GIP 受体双重激动活性，得益于优异的药代动力学 特性，具备每两周注射一次的长效药物潜力。 RAY1225 注射液治疗肥胖/超重患者的 II 期临床试验（REBUILDING-1） ...

Financial Performance - In 2024, the company reported a revenue of CNY 246,741.84 million, with a net loss attributable to shareholders of CNY 29,915.71 million, and a net loss of CNY 26,031.27 million after excluding non-recurring gains [2][4] - The decline in performance was attributed to the impact of centralized procurement pricing on the company's core product, the Compound Thrombus-Resolving Series [2] - Non-recurring gains decreased the net profit attributable to shareholders by CNY 3,884.44 million due to litigation-related provisions [2] Asset Impairment - The total asset impairment loss for 2024 was CNY 54,668.07 million, reducing the net profit attributable to shareholders by CNY 48,409.79 million [5][7] - Major impairment factors included inventory write-downs of CNY 5,472.75 million and goodwill impairment of CNY 20,167.71 million related to subsidiaries [5][7] - The company also recognized an impairment loss of CNY 7,916.66 million on intangible assets [5][7] Q1 2025 Performance - In Q1 2025, the company achieved a revenue of CNY 63,426.14 million, a year-on-year decrease of 1.07% [8] - The net profit attributable to shareholders was CNY 8,261.18 million, a year-on-year increase of 61.06% [8] - The net profit after excluding non-recurring gains was CNY 7,843.48 million, reflecting an increase of 8.60% year-on-year [8] R&D Pipeline - The company has established a multi-mode R&D ecosystem focusing on metabolic and respiratory diseases [9] - The innovative drug ZSP1601 for treating metabolic dysfunction-related fatty liver disease has completed Phase Ib/IIa clinical trials, showing significant reductions in liver inflammation markers [9][14] - The oral antiviral drug, Lai Rui Te Wei (乐睿灵®), has been approved for conditional marketing and included in the national medical insurance directory [10] New Drug Developments - The influenza drug Angrawei (安睿威®) has shown positive results in Phase III clinical trials and is under review for market approval [20] - The GLP-1 receptor agonist RAY1225 has completed Phase II trials, demonstrating significant weight loss and glycemic control in participants [15][18] - RAY1225 is expected to be a bi-weekly administered treatment for type 2 diabetes and obesity, with ongoing Phase III trials [15][18]

证券代码：002317 公告编号：2025-044 广东众生药业股份有限公司 关于使用闲置自有资金进行委托理财的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、概述 广东众生药业股份有限公司（以下简称"公司"）于 2024 年 10 月 26 日召开 了第八届董事会第十六次会议和第八届监事会第十六次会议，审议通过了《关于 使用闲置自有资金进行委托理财的议案》，同意公司及子公司（公司合并报表范 围内的子公司）在保障日常生产经营以及项目建设资金需求，有效控制风险的前 提下，使用不超过人民币 70,000.00 万元的闲置自有资金进行委托理财，期限为 本次董事会审议通过之日起十二个月内，期限内任一时点的交易金额不超过人民 币 70,000.00 万元。在上述期限及额度内，资金可滚动使用。本投资事项将在上 述额度内，授权董事长具体实施相关事宜。 上述具体内容详见公司于 2024 年 10 月 29 日刊载在《证券时报》和巨潮资 讯网（www.cninfo.com.cn）的相关公告。 截至目前，公司使用闲置自有资金购买的结构性保本型产品均已到期，为提 高闲 ...

证券代码：002317 公告编号：2025-043 广东众生药业股份有限公司 关于公司为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 广东众生药业股份有限公司（以下简称"公司"）于 2024 年 4 月 21 日召开 第八届董事会第十三次会议及于 2024 年 5 月 14 日召开的 2023 年年度股东大会 审议通过了《关于公司向合并报表范围内子公司提供担保额度的议案》，为统筹 安排子公司（指"公司合并报表范围内的子公司"，下同）的生产经营活动，确 保子公司的生产经营持续发展，提高资金使用效率，公司继续为子公司向银行申 请信贷业务提供合计不超过人民币 20 亿元额度的连带责任保证。授权董事长在 上述额度内根据具体情况实施相关事宜并签署有关文件。 具体内容详见公司于 2024 年 4 月 23 日及 2024 年 5 月 15 日刊载在《证券 时报》和巨潮资讯网（www.cninfo.com.cn）的相关公告。 近日，为满足日常生产经营的需要，降低融资成本，公司全资子公司广东华 南药业集团有限公司（以下简称"华南药 ...

Core Viewpoint - The company reported a significant decline in performance for 2024, with a revenue of 2.467 billion yuan, down 5.48% year-on-year, and a net loss of 299 million yuan, marking a drastic shift from a profit of 263 million yuan in the previous year [1][4][10] Revenue and Profitability - The company's revenue has been on a downward trend since 2022, with figures of 2.676 billion yuan in 2022, 2.611 billion yuan in 2023, and 2.467 billion yuan in 2024 [2] - The traditional Chinese medicine segment generated 1.318 billion yuan, accounting for 53.93% of total revenue, while chemical drugs contributed 899 million yuan, or 36.81% [2] - The average price of the core product, Compound XueShuanTong series, dropped by 52% after entering national procurement, leading to a revenue decrease of approximately 120 million yuan despite an 18% increase in sales volume [3] Business Segments - The company is undergoing a transformation from traditional Chinese medicine to an innovative pharmaceutical company, focusing on three main business areas: traditional Chinese medicine, chemical drugs, and innovative drugs [1][10] - The chemical generic drug sector is being refined, with six products approved in 2024, while the raw materials and intermediates segment saw a revenue drop of 26.98% to 30.49 million yuan [3][5] R&D and Innovation - The company has a strong commitment to R&D, with a research expense ratio of 10.68% in 2024, despite a decrease from 12.5% in 2023 [8] - The company has halted several clinical projects, resulting in a one-time impairment loss of 207 million yuan, reflecting a focus on core pipelines [8][9] - The innovative drug RAY1225 is projected to generate significant sales in the diabetes and obesity management market, with estimated contributions of 1.369 billion yuan for diabetes and 700 million yuan for weight management by 2033 [9] Asset Management and Impairment - The company recorded an asset impairment loss of 547 million yuan in 2024, primarily due to goodwill impairment related to subsidiaries and R&D projects [6][7] - The goodwill value at the end of 2024 was 318 million yuan, significantly reduced from 530 million yuan in 2023, indicating challenges in integrating acquired assets [6][7] Market Position and Future Outlook - The company is positioned in a critical transition phase, aiming to redefine its industry status and enhance its innovative capabilities [1][10] - The next 2-3 years are crucial for the company to validate its innovative drug commercialization capabilities, with potential risks if core projects face obstacles [10]

Core Viewpoint - The financial performance of the company in 2024 showed a significant decline, with a revenue of 2.467 billion yuan, down 5.48% year-on-year, and a net profit loss of 299 million yuan, a decrease of 213.63% compared to the previous year, primarily due to price reductions from centralized procurement and impairment losses [1][5]. Revenue Breakdown - The company's revenue decline was largely attributed to the impact of centralized procurement on its core products, particularly the Compound Thrombus Tong series, which saw price reductions after being selected for national procurement [3][4]. - The traditional Chinese medicine segment accounted for over 50% of total revenue, with 2023 revenue at 1.391 billion yuan, down 14.86%, and 2024 revenue at 1.318 billion yuan, down 5.25% [3][4]. - The chemical drug segment also experienced a decline, with 2024 revenue of 900 million yuan, down 6.44% [4]. Impairment Losses - The company reported a total impairment loss of 547 million yuan, significantly impacting net profit, with 2024 losses primarily due to goodwill impairment related to subsidiaries [5][6]. - The goodwill from the acquisition of subsidiaries has been fully impaired, with the remaining balance at zero [6]. Innovation Drug Developments - The company established a subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., to focus on innovative drug development, but faced challenges, including a failed IPO and subsequent stock buyback [7][8]. - The innovative drug, Lai Rui Te Wei, received conditional approval but has not yet translated into significant financial returns, with revenues of 57.34 million yuan in 2023 and 40.23 million yuan in 2024 [7][8]. Future Outlook - Analysts suggest that the impact of centralized procurement will be largely absorbed by the second half of 2024, with expectations for a recovery in traditional business and innovative drug segments starting in 2025 [2][6]. - In Q1 2025, the company reported a revenue of 634 million yuan, a slight decrease of 1.07%, but a net profit increase of 61.06% year-on-year, indicating potential operational improvements [9].